A Purified Recombinant Lipopeptide as Adjuvant for Cancer Immunotherapy
Figure 4
CD8+ T cell response and antitumor effect elicited by lipo-Nter in a protein vaccine. (a) C57BL/6 mice were immunized twice by subcutaneous injection with PBS or rE7m (30 μg) mixed with/without lipo-Nter (30 μg/100 μL) at a 2-week interval. On day 7 after the second immunization, the mice were sacrificed, and splenocytes (2 × 105 cells/well) were stimulated with or without 10 μg/mL RAHYNIVTF (RAH) peptide for 48 h in an anti-IFN--coated 96-well ELISPOT plate. The IFN--secreting spots were measured using an ELISPOT reader. (b) 2 × 105 TC-1 cells were injected into the abdominal region of the mice. After 7 days, TC-1 tumor-bearing mice (6 animals/group) received a single injection with PBS or rE7m (30 μg) mixed with or without lipo-Nter (30 μg/100 μL). The tumor diameters are shown (cm3). The data are expressed as the means + SD of 6 animals per group.
